Wendy future of retail top

trastuzumab-dkst

Mylan gains FDA approval for Herceptin biosimilar

Mylan gains FDA approval for Herceptin biosimilar

PITTSBURGH and BENGALURU, India — Mylan N.V. has received Food and Drug Administration approval for Ogivri (trastuzumab-dkst), a biosimilar oncology drug co-developed with Biocon Ltd. Mylan said Friday that Ogivri is a biosimilar of Herceptin (trastuzumab) from Genentech, indicated for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma).

Centrum 7/6  banner